A Chandran1, Pr D Udayakumar2, T A Kermani3, K J Warrington1, C S Crowson4, E L Matteson5. 1. Division of Rheumatology, Department of Medicine, Mayo Clinic College of Medicine, Rochester, MN, USA. 2. Division of Rheumatology, Department of Medicine, Mayo Clinic College of Medicine, Rochester; and Division of Rheumatology, Department of Medicine, University of Minnesota, Minneapolis, MN, USA. 3. Division of Rheumatology, University of California, Los Angeles, CA, USA. 4. Division of Rheumatology, Department of Medicine; and Division of Biomedical Statistics and Informatics, Mayo Clinic College of Medicine, Rochester, MN, USA. 5. Division of Rheumatology, Department of Medicine; and Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, MN, USA.
Abstract
OBJECTIVES: To evaluate the trends in glucocorticoid (GC) therapy in patients with giant cell arteritis (GCA). METHODS: Using a population-based inception cohort, GC therapy details were collected for all patients with GCA diagnosed between 1950-2009. GC usage for patients diagnosed with GCA between 1980-2009 was compared to those diagnosed between 1950-1979. RESULTS: The mean starting dose was similar in both time-periods but the mean cumulative dosages at different time points were significantly higher for patients diagnosed between 1980-2009 than in 1950-1979 (at 1-year: 6.3 vs. 4.1g; and at 5 years 10.7 vs. 7.6g, respectively, p<0.001). The median time to permanent discontinuation of GC was 2.6 years for 1980-2009 vs. 1.5 years for 1950-1979 (p=0.004). The risk for GC-associated adverse events was similar in both time periods (p=0.52). CONCLUSIONS: GCA patients diagnosed in the last three decades were treated with higher cumulative GC doses and were less likely to achieve GC discontinuation. However, their risks for GC-related complications were not significantly higher than their earlier counterparts.
OBJECTIVES: To evaluate the trends in glucocorticoid (GC) therapy in patients with giant cell arteritis (GCA). METHODS: Using a population-based inception cohort, GC therapy details were collected for all patients with GCA diagnosed between 1950-2009. GC usage for patients diagnosed with GCA between 1980-2009 was compared to those diagnosed between 1950-1979. RESULTS: The mean starting dose was similar in both time-periods but the mean cumulative dosages at different time points were significantly higher for patients diagnosed between 1980-2009 than in 1950-1979 (at 1-year: 6.3 vs. 4.1g; and at 5 years 10.7 vs. 7.6g, respectively, p<0.001). The median time to permanent discontinuation of GC was 2.6 years for 1980-2009 vs. 1.5 years for 1950-1979 (p=0.004). The risk for GC-associated adverse events was similar in both time periods (p=0.52). CONCLUSIONS: GCA patients diagnosed in the last three decades were treated with higher cumulative GC doses and were less likely to achieve GC discontinuation. However, their risks for GC-related complications were not significantly higher than their earlier counterparts.
Authors: G G Hunder; D A Bloch; B A Michel; M B Stevens; W P Arend; L H Calabrese; S M Edworthy; A S Fauci; R Y Leavitt; J T Lie Journal: Arthritis Rheum Date: 1990-08
Authors: Alwin Sebastian; Kornelis S M van der Geest; Fiona Coath; Prisca Gondo; Abdul Kayani; Craig Mackerness; Bernard Hadebe; Sue Innes; Jo Jackson; Bhaskar Dasgupta Journal: BMC Rheumatol Date: 2020-08-18
Authors: Tanaz A Kermani; Antoine G Sreih; David Cuthbertson; Simon Carette; Gary S Hoffman; Nader A Khalidi; Curry L Koening; Carol A Langford; Carol A McAlear; Paul A Monach; Larry Moreland; Christian Pagnoux; Philip Seo; Kenneth J Warrington; Steven R Ytterberg; Peter A Merkel Journal: Rheumatology (Oxford) Date: 2018-02-01 Impact factor: 7.580
Authors: Paul Castan; Anael Dumont; Samuel Deshayes; Jonathan Boutemy; Nicolas Martin Silva; Gwénola Maigné; Alexandre Nguyen; Sophie Gallou; Audrey Sultan; Achille Aouba; Hubert de Boysson Journal: J Clin Med Date: 2022-02-16 Impact factor: 4.241
Authors: Wolfgang A Schmidt; Bhaskar Dasgupta; Raashid Luqmani; Sebastian H Unizony; Daniel Blockmans; Zhihong Lai; Regina H Kurrasch; Ivana Lazic; Kurt Brown; Ravi Rao Journal: Rheumatol Ther Date: 2020-08-25
Authors: Pavlos Stamatis; Aleksandra Turkiewicz; Martin Englund; Carl Turesson; Aladdin J Mohammad Journal: Rheumatology (Oxford) Date: 2021-12-24 Impact factor: 7.580